Related Experiment Video

Updated: Dec 10, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K

Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"

Carmen Balana1,2, Cristina Carrato3, Maria Angeles Vaz4

  • 1Medical Oncology Service, Catalonian Institute of Oncology, Badalona, Spain.

Neuro-Oncology
|September 5, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Related Experiment Videos

Last Updated: Dec 10, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort.

Cancer medicine·2026

Histopathologic Features of Cutaneous Plexiform Schwannomas in Neurofibromatosis Type 2-Related Schwannomatosis: Analysis of a Series of 19 Cases.

Journal of cutaneous pathology·2026

Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study.

Journal of the Endocrine Society·2026

Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study.

NPJ precision oncology·2026

14-3-3σ up-regulation in the temporal cortex associates with tau pathology and reactive astroglia in Lewy body disorders.

Brain pathology (Zurich, Switzerland)·2025

Cancer Neuroscience: Establishing a home in Neuro-Oncology.

Neuro-oncology·2026

Glioma and ependymoma through the lens of brain development, stem cells, and plasticity.

Neuro-oncology·2026

Impact of [18F]FET-PET on MRI-Based Radiotherapy Target Volumes in Newly Diagnosed Glioblastoma:Results from the FET-PET in Glioblastoma (FIG) Study TROG 18.06.

Neuro-oncology·2026

Potentially inappropriate care at the end of life in patients with glioblastoma: A single-center observational cohort study.

Neuro-oncology·2026

Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma.

Neuro-oncology·2026

Immune Cell Engager Therapy for Brain Cancer.

Neuro-oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us